BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 29264364)

  • 21. The use of immunocompromised animals as models for human septic shock.
    Opal SM; Cross AS
    Shock; 2005 Dec; 24 Suppl 1():64-70. PubMed ID: 16374375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sepsis-Pathophysiology and Therapeutic Concepts.
    Jarczak D; Kluge S; Nierhaus A
    Front Med (Lausanne); 2021; 8():628302. PubMed ID: 34055825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic insights into sepsis: what have we learned and how will it help?
    Wurfel MM
    Curr Pharm Des; 2008; 14(19):1900-11. PubMed ID: 18691101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sepsis-Induced Immunosuppression in Neonates.
    Hibbert JE; Currie A; Strunk T
    Front Pediatr; 2018; 6():357. PubMed ID: 30555806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Innate immunity in sepsis pathogenesis and its modulation: new immunomodulatory targets revealed.
    Kumar V; Sharma A
    J Chemother; 2008 Dec; 20(6):672-83. PubMed ID: 19129063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IL-7 and Its Beneficial Role in Sepsis-Induced T Lymphocyte Dysfunction.
    de Roquetaillade C; Monneret G; Gossez M; Venet F
    Crit Rev Immunol; 2018; 38(6):433-451. PubMed ID: 31002599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sepsis and septic shock: pathophysiological and cardiovascular background as basis for therapy.
    De Kock I; Van Daele C; Poelaert J
    Acta Clin Belg; 2010; 65(5):323-9. PubMed ID: 21128559
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of patients with sepsis and septic shock after ICU treatment.
    Schoenberg MH; Weiss M; Radermacher P
    Langenbecks Arch Surg; 1998 Mar; 383(1):44-8. PubMed ID: 9627170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The REAnimation Low Immune Status Markers (REALISM) project: a protocol for broad characterisation and follow-up of injury-induced immunosuppression in intensive care unit (ICU) critically ill patients.
    Rol ML; Venet F; Rimmele T; Moucadel V; Cortez P; Quemeneur L; Gardiner D; Griffiths A; Pachot A; Textoris J; Monneret G;
    BMJ Open; 2017 Jun; 7(6):e015734. PubMed ID: 28637738
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel potential therapies for septic shock.
    Azevedo LC; Park M; Schettino GP
    Shock; 2008 Oct; 30 Suppl 1():60-6. PubMed ID: 18704007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of the adaptive immune response in sepsis.
    Brady J; Horie S; Laffey JG
    Intensive Care Med Exp; 2020 Dec; 8(Suppl 1):20. PubMed ID: 33336293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New perspectives on immunomodulatory therapy for bacteraemia and sepsis.
    Opal SM
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S70-3. PubMed ID: 21129935
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sepsis: time has come to focus on the later stages.
    Schefold JC; Hasper D; Volk HD; Reinke P
    Med Hypotheses; 2008 Aug; 71(2):203-8. PubMed ID: 18448264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sepsis in PD-1 light.
    Monneret G; Gossez M; Venet F
    Crit Care; 2016 Jul; 20(1):186. PubMed ID: 27378029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sirtuin1 Targeting Reverses Innate and Adaptive Immune Tolerance in Septic Mice.
    Martin AN; Alexander-Miller M; Yoza BK; Vachharajani V; McCall CE
    J Immunol Res; 2018; 2018():2402593. PubMed ID: 30069485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of age on the innate immune response and outcomes after severe sepsis/septic shock in trauma and surgical intensive care unit patients.
    Brakenridge SC; Efron PA; Stortz JA; Ozrazgat-Baslanti T; Ghita G; Wang Z; Bihorac A; Mohr AM; Brumback BA; Moldawer LL; Moore FA
    J Trauma Acute Care Surg; 2018 Aug; 85(2):247-255. PubMed ID: 29613958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil Activation During Septic Shock.
    Stiel L; Meziani F; Helms J
    Shock; 2018 Apr; 49(4):371-384. PubMed ID: 28858142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Post-infectious immune suppression: a new paradigm of severe infections.
    Grimaldi D; Llitjos JF; Pène F
    Med Mal Infect; 2014 Oct; 44(10):455-63. PubMed ID: 25169939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of Dendritic Cell Responses to Sepsis-Induced Immunosuppression and to Susceptibility to Secondary Pneumonia.
    Bouras M; Asehnoune K; Roquilly A
    Front Immunol; 2018; 9():2590. PubMed ID: 30483258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Host-pathogen interactions in sepsis.
    van der Poll T; Opal SM
    Lancet Infect Dis; 2008 Jan; 8(1):32-43. PubMed ID: 18063412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.